von Tobias Borgers | Feb. 15, 2022 | Glaxo
Curevo has raised $60 million to develop a new vaccine for shingles, an often-painful condition caused by reactivation of the chickenpox virus. The new funding will enable the Seattle-based startup to test its vaccine against a market-commanding shot made by...
von Tobias Borgers | Jan. 4, 2022 | Glaxo
EMERYVILLE, Calif.–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK). The expansion will leverage...
von Tobias Borgers | Jan. 4, 2022 | Glaxo
September 13, 2021 | When Mike Montello joined the GSK team, the first steps of the pharma’s digital transformation had already taken place. His focus was to integrate the enterprise digital transformation to support another transformation taking place in R&D. “We...
von Tobias Borgers | Aug. 24, 2021 | Glaxo, Markt
For media and investors only Issued: London UK and Tübingen, Germany / Boston, USA Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s...
von Tobias Borgers | Juli 15, 2021 | Glaxo
New drug approvals are the holy grail for pharmas big and small, but a slate of regulatory nods doesn’t automatically translate to top performance. In the last five years, the world’s top 11 drugmakers have brought 76 new meds to market, Evaluate Vantage said...
von Tobias Borgers | Jan. 7, 2021 | Glaxo
GSK Ulverston is looking for driven candidates who are passionate about pursuing a career in manufacturing or engineering, which are available to all school leavers who have achieved or are predicted to achieve the minimum academic requirements. In 2020 the Zinnat...
